Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Clinical implications and management of oestrogen deficiency in the male.

Balestrieri A, Faustini-Fustini M, Rochira V, Carani C.

Clin Endocrinol (Oxf). 2001 Apr;54(4):431-2. Review. No abstract available.

PMID:
11318776
2.

Novel treatment of short stature with aromatase inhibitors.

Dunkel L, Wickman S.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):345-56.

PMID:
14623531
3.
4.

Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men.

Rochira V, Balestrieri A, Madeo B, Spaggiari A, Carani C.

Mol Cell Endocrinol. 2002 Jul 31;193(1-2):19-28. Review.

PMID:
12160998
5.

Pharmacological management of children with short stature: the role of aromatase inhibitors.

Damiani D, Damiani D.

J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S172-7. Epub 2007 Sep 28. Review.

6.

Aromatase deficiency in men: a clinical perspective.

Rochira V, Carani C.

Nat Rev Endocrinol. 2009 Oct;5(10):559-68. doi: 10.1038/nrendo.2009.176. Epub 2009 Aug 25. Review.

PMID:
19707181
7.

A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.

Maffei L, Rochira V, Zirilli L, Antunez P, Aranda C, Fabre B, Simone ML, Pignatti E, Simpson ER, Houssami S, Clyne CD, Carani C.

Clin Endocrinol (Oxf). 2007 Aug;67(2):218-24. Epub 2007 Jun 4.

PMID:
17547681
8.

Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency.

Rochira V, Balestrieri A, Faustini-Fustini M, Carani C.

Mol Cell Endocrinol. 2001 Jun 10;178(1-2):215-20. Review.

PMID:
11403912
9.

Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency.

Zhou P, Shah B, Prasad K, David R.

Pediatrics. 2005 Feb;115(2):e245-8. Epub 2005 Jan 14.

PMID:
15653791
10.

Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.

Rochira V, Zirilli L, Genazzani AD, Balestrieri A, Aranda C, Fabre B, Antunez P, Diazzi C, Carani C, Maffei L.

Eur J Endocrinol. 2006 Oct;155(4):513-22.

11.
12.

[Climacteric disorders].

Makita K, Horiguchi F, Aoki D.

Nihon Rinsho. 2006 Apr;64 Suppl 4:394-9. Review. Japanese. No abstract available.

PMID:
16689340
13.

Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy.

Kawai H, Furuhashi M, Suganuma N.

Arch Gynecol Obstet. 2004 Mar;269(3):192-5. Epub 2003 Sep 12.

PMID:
13680264
14.

Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.

Rochira V, Zirilli L, Madeo B, Aranda C, Caffagni G, Fabre B, Montangero VE, Roldan EJ, Maffei L, Carani C.

Bone. 2007 Jun;40(6):1662-8. Epub 2007 Feb 27.

PMID:
17400043
15.

A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment.

Lanfranco F, Zirilli L, Baldi M, Pignatti E, Corneli G, Ghigo E, Aimaretti G, Carani C, Rochira V.

Bone. 2008 Sep;43(3):628-35. doi: 10.1016/j.bone.2008.05.011. Epub 2008 May 23.

PMID:
18590994
16.

Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.

Fukami M, Miyado M, Nagasaki K, Shozu M, Ogata T.

Pediatr Endocrinol Rev. 2014 Mar;11(3):298-305. Review.

PMID:
24716396
17.

Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.

Roth C, Freiberg C, Zappel H, Albers N.

J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.

PMID:
12199354
18.

Aromatase inhibition, testosterone, and seizures.

Harden C, MacLusky NJ.

Epilepsy Behav. 2004 Apr;5(2):260-3.

PMID:
15123030
19.

Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.

Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C.

J Clin Endocrinol Metab. 2004 Jan;89(1):61-70.

PMID:
14715828
20.

Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection.

McCullough LD, Blizzard K, Simpson ER, Oz OK, Hurn PD.

J Neurosci. 2003 Sep 24;23(25):8701-5.

Items per page

Supplemental Content

Write to the Help Desk